These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 11010775)
1. Botulinum toxin: new treatment for temporomandibular disorders. Freund B; Schwartz M; Symington JM Br J Oral Maxillofac Surg; 2000 Oct; 38(5):466-71. PubMed ID: 11010775 [TBL] [Abstract][Full Text] [Related]
2. The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings. Freund B; Schwartz M; Symington JM J Oral Maxillofac Surg; 1999 Aug; 57(8):916-20; discussion 920-1. PubMed ID: 10437718 [TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens. Slawek J; Bogucki A; Reclawowicz D Neurol Sci; 2005 Apr; 26(1):32-9. PubMed ID: 15877185 [TBL] [Abstract][Full Text] [Related]
4. Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: a pilot study. Freund BJ; Schwartz M J Rheumatol; 2000 Feb; 27(2):481-4. PubMed ID: 10685817 [TBL] [Abstract][Full Text] [Related]
5. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis]. Wissel J; Entner T Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048 [TBL] [Abstract][Full Text] [Related]
6. A prospective randomized controlled study of the role of botulinum toxin in whiplash-associated disorder. Carroll A; Barnes M; Comiskey C Clin Rehabil; 2008 Jun; 22(6):513-9. PubMed ID: 18511531 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. Jeffery S; Fynes M; Lee F; Wang K; Williams L; Morley R BJU Int; 2007 Dec; 100(6):1302-6. PubMed ID: 17979928 [TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study. Harden RN; Cottrill J; Gagnon CM; Smitherman TA; Weinland SR; Tann B; Joseph P; Lee TS; Houle TT Headache; 2009 May; 49(5):732-43. PubMed ID: 19178577 [TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin type-A (BOTOX) in the treatment of occipital neuralgia: a pilot study. Taylor M; Silva S; Cottrell C Headache; 2008; 48(10):1476-81. PubMed ID: 19076646 [TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin-A injections via electrical motor point stimulation to treat writer's cramp: pilot study. Lim EC; Quek AM; Seet RC Neurol Neurophysiol Neurosci; 2006 Jun; ():4. PubMed ID: 17260081 [TBL] [Abstract][Full Text] [Related]
11. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Giannantoni A; Costantini E; Di Stasi SM; Tascini MC; Bini V; Porena M Eur Urol; 2006 Apr; 49(4):704-9. PubMed ID: 16417964 [TBL] [Abstract][Full Text] [Related]
12. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Mancini F; Sandrini G; Moglia A; Nappi G; Pacchetti C Neurol Sci; 2005 Apr; 26(1):26-31. PubMed ID: 15877184 [TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R; Schreiber C Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [TBL] [Abstract][Full Text] [Related]
14. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter? Carruthers A; Carruthers J; Cohen J Dermatol Surg; 2007 Jan; 33(1 Spec No.):S97-104. PubMed ID: 17241422 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Schulte-Baukloh H; Schobert J; Stolze T; Stürzebecher B; Weiss C; Knispel HH Neurourol Urodyn; 2006; 25(2):110-5. PubMed ID: 16470519 [TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ranoux D; Attal N; Morain F; Bouhassira D Ann Neurol; 2008 Sep; 64(3):274-83. PubMed ID: 18546285 [TBL] [Abstract][Full Text] [Related]
17. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Elovic EP; Brashear A; Kaelin D; Liu J; Millis SR; Barron R; Turkel C Arch Phys Med Rehabil; 2008 May; 89(5):799-806. PubMed ID: 18452724 [TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin injections for new onset bilateral vocal fold motion impairment in adults. Ekbom DC; Garrett CG; Yung KC; Johnson FL; Billante CR; Zealear DL; Courey MS Laryngoscope; 2010 Apr; 120(4):758-63. PubMed ID: 20213793 [TBL] [Abstract][Full Text] [Related]
19. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859 [TBL] [Abstract][Full Text] [Related]
20. Type A botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction. von Lindern JJ Acta Neurol Belg; 2001 Mar; 101(1):39-41. PubMed ID: 11379274 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]